<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457158</url>
  </required_header>
  <id_info>
    <org_study_id>0501105</org_study_id>
    <secondary_id>2006-01-001</secondary_id>
    <nct_id>NCT00457158</nct_id>
  </id_info>
  <brief_title>PREPIC 2 : Prevention of Recurrent Pulmonary Embolism by Vena Cava Interruption</brief_title>
  <acronym>PREPIC2</acronym>
  <official_title>PREPIC 2 : Interruption of Inferior Vena Cava by a Retrievable Filter for the Prevention of Recurrent Pulmonary Embolism : a Randomised, Open Label Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation de France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondation de l'Avenir</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ALN Implants Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess efficacy and safety of optional vena cava filter
      implanted 3 months in prevention of recurrent pulmonary embolism in patients presenting with
      acute pulmonary embolism associated with thrombotic risk factors
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pulmonary embolism is a common pathology, which could be fatal (about 10 000 death/year in
      France). It mainly originates from a deep vein thrombosis. In order to reduce mortality,
      prevention of new or recurrent PE is a major therapeutic aim. Only one randomised trial
      (PREPIC) assessed the interest of a vena cava filter in patients treated by anticoagulant
      treatment for a deep vein thrombosis (DVT). Results show a significant 50 % reduction of the
      embolic risk with the filter. This benefit occurs from the first days, but are
      counterbalanced by a long-term increasing risk of recurrent DVT. The filter appears promising
      in patients with a high risk of PE, for exemple the elderly, presenting with a thromboembolic
      history, cancer, heart failure or respiratory insufficiency, or a recent PE. Moreover,
      retrievable filters, which may be either left in place permanently or retrieved after some
      days or weeks, could limit the filter thrombosis risk.

      The aim of PREPIC 2 study is to assess, in a multicenter randomised trial, efficacy and
      safety of a retrievable vena cava filter implanted 3 months versus no filter in 400 patients
      treated with anticoagulant drugs for a symptomatic PE associated with at least one thrombotic
      risk factor. A clinical follow-up will be performed at 6 months. The primary outcome is the
      incidence of recurrent PE at 3 months, including symptomatic and fatal PE. It will be
      adjudicated by an independent committee, blinded to patients' allocation.

      This study will assess the benefit risk ratio of the retrievable filter for the prevention of
      recurrent PE, without increasing the thrombotic risk and the disadvantage due to post
      thrombotic syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>at 3 months, combined criteria including recurrent PE confirmed by objective tests and fatal PE confirmed by autopsy and death which can not be attribuated to a documented cause and for which PE/DVT can't be ruled out</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrent pulmonary embolism, fatal or not, at 6 months (combined criteria including recurrent pulmonary ambolism confirmed by objective tests and fatal PE confirmed by autopsy and death which can not be attribuated to a documented cause and for which P</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>current or new symptomatic DVT confirmed by objective tests</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mecanical complication of filter (migration, tilt, transfixion) and or puncture site hematoma, and/or local or general infection due to filter</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>filter thrombosis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>filter retrieval failure</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total death</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">399</enrollment>
  <condition>Pulmonary Embolism</condition>
  <condition>Venous Thrombosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALN optional filter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No ALN optional filter</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ALN optional filter</intervention_name>
    <description>J1 : ALN optional filter M3 : ALN optional filter removed</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Acute symptomatic pulmonary embolism; AND

          -  Deep or superficial vein thrombosis; AND

          -  At least one of the risk factors below :

               -  More than 75 years old

               -  Evolutiv cancer (excepting locally cutaneous cancer)

               -  Known chronic heart failure treated

               -  Chronic respiratory insufficiency treated

               -  Bilateral deep vein thrombosis

               -  Ilio-cava thrombosis

               -  Ischemic stroke &gt; 3 days and &lt; 6 months, with lower limb deficit

               -  Cardiac repercussion of pulmonary embolism assessed by echocardiography or
                  increasing troponin I or T, or Brain Natriuretic Peptid or proBNP

        Exclusion Criteria:

          -  Contrindication to an anticoagulant treatment or recurrent thromboembolic event
             despite adequate anticoagulation

          -  Vena cava filter already inserted

          -  Filter insertion impossible due to caval thrombosis

          -  More than 72 hours pre-randomized treatment with therapeutic dosage of anticoagulant
             therapy

          -  Non carcinologic surgery within 3 months prior randomization

          -  Carcinologic surgery within 10 days prior randomization

          -  Hypersensitivity to contrast media

          -  Access port in place or programmed within 3 months

          -  Woman who are child bearing

          -  Life expectancy &lt; 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick MISMETTI, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Médecine Vasculaire, CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80080</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Accueil des Urgences, CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Cardiologie, CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de Medecine Interne et Pneumologie, CHU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie, Hôpital Antoine Beclere</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Accueil des Urgences, CHU de Clermont Ferrand</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service des Urgences, CHG de Firminy</name>
      <address>
        <city>Firminy</city>
        <zip>42700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unité de Médecine Vasculaire, CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urgences Soins Intensifs cardiologiques, CHU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Medecine Interne et Maladies Vasculaires, CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Medecine Interne et Vasculaire, CHU de Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Cardiologie, CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de Pneumologie, Hôpital Européen Georges Pompidou, AP HP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Urgences et de Réanimation Medicale, CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Medecine et Therapeutique - CHU de Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Vasculaire, CH Toulon</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Cardiologie, CHU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, Laporte S, Faivre R, Charbonnier B, Barral FG, Huet Y, Simonneau G. A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med. 1998 Feb 12;338(7):409-15.</citation>
    <PMID>9459643</PMID>
  </reference>
  <reference>
    <citation>PREPIC Study Group. Eight-year follow-up of patients with permanent vena cava filters in the prevention of pulmonary embolism: the PREPIC (Prevention du Risque d'Embolie Pulmonaire par Interruption Cave) randomized study. Circulation. 2005 Jul 19;112(3):416-22. Epub 2005 Jul 11.</citation>
    <PMID>16009794</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2007</study_first_posted>
  <last_update_submitted>November 22, 2012</last_update_submitted>
  <last_update_submitted_qc>November 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary embolism</keyword>
  <keyword>inferior vena cava filters</keyword>
  <keyword>venous thrombosis</keyword>
  <keyword>randomized controlled trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

